en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


 
1/2021
vol. 59
 
Share:
Share:
more
 
 
abstract:
Case-based review

Ustekinumab-induced chronic lymphocytic leukemia in a patient with psoriatic arthritis

Fusun Gediz
1
,
Mehmet Can Ugur
1
,
Meltem Turkmen
2
,
Senol Kobak
3

1.
Department of Hematology, University of Health Sciences, İzmir Bozyaka Training and Research Hospital, Turkey
2.
Department of Dermatology,, University of Health Sciences, İzmir Bozyaka Training and Research Hospital, Turkey
3.
Department of Rheumatology, Faculty of Medicine, Istinye University, LIV Hospital, Istanbul, Turkey
Reumatologia 2021; 59, 1: 58–61
Online publish date: 2021/02/28
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Psoriatic arthritis (PsA) is a chronic inflammatory disease characterized by skin and joint involvement. The disease may present with various joint pattern involvement, which sometimes may lead to joint destruction and deformity. Early diagnosis and treatment with disease-modifying anti-rheumatic drugs may prevent joint deformity. Recently there are many new treatment options including biologic drugs. Ustekinumab, an interleukin 12/23 inhibitor, has proven efficacy in the treatment of psoriatic arthritis. Like other biologic drugs (anti-TNF-), there are contradictory data about the safety of ustekinumab and possible relationship with cancer development.

Herein we report the development of chronic lymphocytic leukemia in a patient with PsA treated with ustekinumab.
keywords:

psoriatic arthritis, ustekinumab, chronic lymphocytic leukemia







Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.